4-hydroperoxy Cyclophosphamide (Synonyms: 4-OOH-CY) |
| Catalog No.GC42401 |
4-hydroperoxy Cyclophosphamide, el metabolito activo de la ciclofosfamida, puede entrecruzar el ADN e inducir la apoptosis de células T de manera independiente de la activación de los receptores de caspasa. Además, activa la vía mitocondrial de muerte celular mediante la producción de especies reactivas de oxígeno (ROS).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 39800-16-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
4-hydroperoxy Cyclophosphamide, el metabolito activo de la ciclofosfamida, puede entrecruzar el ADN e inducir la apoptosis de células T de manera independiente de la activación de los receptores de caspasa. Además, activa la vía mitocondrial de muerte celular mediante la producción de especies reactivas de oxígeno (ROS). La 4-hidroperoxi Ciclofosfamida es útil en la investigación sobre la artritis reumatoide y enfermedades autoinmunes[1-2].
La 4-hidroperoxi Ciclofosfamida (1 μg/mL, 72-96 h), junto con metotrexato, suprime la expresión de RANKL en sinoviocitos fibroblastos similares estimulados con IL-6/sIL-6R inhibiendo las vías de señalización JAK2/STAT3 y p38MAPK[3]. El tratamiento con 4-hidroperoxi Ciclofosfamida (3 μg/ml; 48h) resultó en la producción de especies reactivas de oxígeno, niveles elevados de Bax y la translocación de los factores mitocondriales factor inductor de apoptosis (AIF) y endonucleasa G (EndoG) al núcleo. Este tratamiento causa muerte celular independiente de caspasa en células CTL humanas [4].
La 4-hidroperoxi Ciclofosfamida (200 mg/kg; i.p.; 5 días) indujo muerte celular independiente de caspasa en células T y B de ratones[4]. La inyección intradérmica de 4-hidroperoxi Ciclofosfamida (50-200 μg) en el sitio sensibilizado en modelos de cobayos de hipersensibilidad de contacto in-vivo resultó en un aumento significativo de la hipersensibilidad de contacto [5].
References:
[1]. Fleer R, Brendel M. Toxicity, interstrand cross-links and DNA fragmentation induced by 'activated' cyclophosphamide in yeast: comparative studies on 4-hydroperoxy-cyclophosphamide, its monofunctional analogon, acrolein, phosphoramide mustard, and nor-nitrogen mustard. Chem Biol Interact. 1982 Mar 1;39(1):1-15. doi: 10.1016/0009-2797(82)90002-3. PMID: 7037214.
[2]. Chen Y, Ai L, et,al. The EZH2-H3K27me3 axis modulates aberrant transcription and apoptosis in cyclophosphamide-induced ovarian granulosa cell injury. Cell Death Discov. 2023 Nov 14;9(1):413. doi: 10.1038/s41420-023-01705-6. PMID: 37963880; PMCID: PMC10646043.
[3]. Niu HQ, Zhao WP, et,al. Combination of 4-hydroperoxy cyclophosphamide and methotrexate inhibits IL-6/sIL-6R-induced RANKL expression in fibroblast-like synoviocytes via suppression of the JAK2/STAT3 and p38MAPK signaling pathway. Int Immunopharmacol. 2018 Aug;61:45-53. doi: 10.1016/j.intimp.2018.05.014. Epub 2018 May 24. PMID: 29803913.
[4]. Strauss G, Westhoff MA, et,al. 4-hydroperoxy-cyclophosphamide mediates caspase-independent T-cell apoptosis involving oxidative stress-induced nuclear relocation of mitochondrial apoptogenic factors AIF and EndoG. Cell Death Differ. 2008 Feb;15(2):332-43. doi: 10.1038/sj.cdd.4402272. Epub 2007 Nov 23. PMID: 18034189.
[5]. Boerrigter GH, de Groot J, et,al. Intradermal administration of 4-hydroperoxy-cyclophosphamide during contact sensitization potentiates effector T cell responsiveness in draining lymph nodes. Immunopharmacology. 1986 Feb;11(1):13-20. doi: 10.1016/0162-3109(86)90060-3. PMID: 3485619.
| Experimentos celulares [1]: | |
Líneas celulares | Linfocitos T citotóxicos humanos primarios (CTL) |
Método de preparación | Las células fueron cultivadas en ausencia (sin tratamiento) o en presencia de 4-hidroperoxi Ciclofosfamida (3 μg/ml) durante 48 h. |
Condiciones de reacción | 3 μg/ml; 48h |
Áreas de aplicación | La 4-hidroperoxi Ciclofosfamida induce la muerte independiente de caspasa en los linfocitos T citotóxicos humanos (CTL) después del tratamiento. |
| Experimentos con animales [1]: | |
Modelos animales | Ratones BALB/c |
Método de preparación | Los ratones fueron inyectados por vía intraperitoneal (i.p.) con 200 mg/kg de 4-hidroperoxi Ciclofosfamida. |
Forma de dosificación | 200 mg/kg; i.p.; 5 días |
Áreas de aplicación | El tratamiento con 4-hidroperoxi Ciclofosfamida induce la muerte independiente de caspasa en las células T y B de los ratones. |
Referencias: [1]. Strauss G, Westhoff MA, et al. 4-hydroperoxy-cyclophosphamide mediates caspase-independent T-cell apoptosis involving oxidative stress-induced nuclear relocation of mitochondrial apoptogenic factors AIF and EndoG. Cell Death Differ. 2008 Feb;15(2):332-43. doi: 10.1038/sj.cdd.4402272. Epub 2007 Nov 23. PMID: 18034189. | |
| Cas No. | 39800-16-3 | SDF | |
| Sinónimos | 4-OOH-CY | ||
| Chemical Name | 2-[bis(2-chloroethyl)amino]tetrahydro-2-oxido-2H-1,3,2-oxazaphosphorin-4-yl, hydroperoxide | ||
| Canonical SMILES | O=P1(N(CCCl)CCCl)OCCC(OO)N1 | ||
| Formula | C7H15Cl2N2O4P | M.Wt | 293.1 |
| Solubility | DMSO : 50 mg/mL (170.60 mM; Need ultrasonic) | Storage | -80°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.4118 mL | 17.059 mL | 34.118 mL |
| 5 mM | 0.6824 mL | 3.4118 mL | 6.8236 mL |
| 10 mM | 0.3412 mL | 1.7059 mL | 3.4118 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 21 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *